UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease

The American journal of gastroenterology, 2022-07, Vol.117 (7), p.1106-1117

2022

Volltextzugriff (PDF)

Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission

Digestive diseases and sciences, 2023-06, Vol.68 (6), p.2658-2666

2023

Volltextzugriff (PDF)

Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial

The American journal of gastroenterology, 2020-08, Vol.115 (8), p.1236-1245

2020

Volltextzugriff (PDF)

Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study

Digestive diseases and sciences, 2023-06, Vol.68 (6), p.2635-2646

2023

Volltextzugriff (PDF)

Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease

The American journal of gastroenterology, 2024-07, Vol.119 (7), p.1355-1364

2024

Volltextzugriff (PDF)

Resolution of dominant patient‐reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease

Alimentary pharmacology & therapeutics, 2022-05, Vol.55 (9), p.1151-1159

2022

Volltextzugriff (PDF)

Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study

The American journal of gastroenterology, 2023-01, Vol.118 (1), p.121-128

2023

Volltextzugriff (PDF)

The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies

United European gastroenterology journal, 2021-06, Vol.9 (5), p.581-589

2021

Volltextzugriff (PDF)

Correspondence on “PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system” by Gui et al

Gut, 2023-04, Vol.72 (4), p.805-807

2023

Volltextzugriff (PDF)

Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY

European journal of gastroenterology & hepatology, 2024-06, Vol.36 (6), p.704-711

2024

Volltextzugriff (PDF)

Food Processing and Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Clinical gastroenterology and hepatology, 2023-09, Vol.21 (10), p.2483-2495.e1

2023

Volltextzugriff (PDF)

Expression of Brain-Derived Neurotrophic Factor in Human Spiral Ganglia Neurons after Cochlear Implantation

Otology & neurotology, 2024-03, Vol.45 (3), p.326-333

2024

Volltextzugriff (PDF)

Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD)

Gut, 2022-06, Vol.71 (6), p.1078-1087

2022

Volltextzugriff (PDF)

Does a High-inflammatory Diet Increase the Risk of Inflammatory Bowel Disease? Results From the Prospective Urban Rural Epidemiology (PURE) Study: A Prospective Cohort Study

Gastroenterology (New York, N.Y. 1943), 2021-10, Vol.161 (4), p.1333-1335.e1

2021

Volltextzugriff (PDF)

Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis

Clinical gastroenterology and hepatology, 2022-05, Vol.20 (5), p.1095-1104.e9

2022

Volltextzugriff (PDF)

Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn’s Disease

Clinical gastroenterology and hepatology, 2022-07, Vol.20 (7), p.1579-1587.e2

2022

Volltextzugriff (PDF)

Beyond the White Pill: Advocating for Racial Diversity in IBD Trials

Journal of Crohn's and colitis, 2023-04, Vol.17 (3), p.459-461

2023

Volltextzugriff (PDF)

Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders

Clinical gastroenterology and hepatology, 2023-12, Vol.21 (13), p.3387-3396.e1

2023

Volltextzugriff (PDF)

Defining Endoscopic Remission in Crohn’s Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease Progression

Clinical gastroenterology and hepatology, 2024-08, Vol.22 (8), p.1687-1696.e6

2024

Volltextzugriff (PDF)

Predictors of histologic response to mepolizumab in pediatric eosinophilic esophagitis

European journal of gastroenterology & hepatology, 2023-10, Vol.35 (10), p.1131-1136

2023

Volltextzugriff (PDF)

Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn’s Disease: A Post Hoc Analysis of the IM-UNITI Trial

Inflammatory bowel diseases, 2021-05, Vol.27 (6), p.848-854

2021

Volltextzugriff (PDF)

Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn’s Disease

Inflammatory bowel diseases, 2023-07, Vol.29 (7), p.1015-1023

2023

Volltextzugriff (PDF)

REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study

The American journal of gastroenterology, 2023-05, Vol.118 (5), p.861-871

2023

Volltextzugriff (PDF)

Clinical Decision Support Tool for Infliximab in Crohn’s Disease

Clinical gastroenterology and hepatology, 2022-05, Vol.20 (5), p.e1192-e1195

2022

Volltextzugriff (PDF)

Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis

Clinical gastroenterology and hepatology, 2022-07, Vol.20 (7), p.1588-1597.e3

2022

Volltextzugriff (PDF)

1 – 25 von 826

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(776)
Mit Volltextzugriff
(691)

Publikationsform

Sprache

Englisch
(825)
Chinesisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(583)
Life Sciences & Biomedicine
(522)
Humans
(365)
Female
(171)
Male
(154)
Animals
(115)
Adult
(95)
Middle Aged
(79)
Aged
(70)
Mice
(65)
Child
(58)
General & Internal Medicine
(58)
Oncology
(58)
Patients
(52)
Gastroenterology & Hepatology
(51)
Adolescent
(50)
Neurosciences & Neurology
(49)
Risk Factors
(49)
Medicine, General & Internal
(46)
Science & Technology - Other Topics
(45)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Gastroenterology
(21)
Alzheimer's & Dementia
(20)
Cancer Research
(17)
Clinical Gastroenterology And Hepatology
(14)
Nature
(14)
Plos One
(13)
Blood
(11)
Journal Of Clinical Oncology
(11)
The New England Journal Of Medicine
(11)
Journal Of Crohn's And Colitis
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease

Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission

Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial

Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study

Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease

Resolution of dominant patient‐reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease

Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study

The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies

Correspondence on “PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system” by Gui et al

Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY

Food Processing and Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Expression of Brain-Derived Neurotrophic Factor in Human Spiral Ganglia Neurons after Cochlear Implantation

Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD)

Does a High-inflammatory Diet Increase the Risk of Inflammatory Bowel Disease? Results From the Prospective Urban Rural Epidemiology (PURE) Study: A Prospective Cohort Study

Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis

Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn’s Disease

Beyond the White Pill: Advocating for Racial Diversity in IBD Trials

Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders

Defining Endoscopic Remission in Crohn’s Disease: MM-SES-CD and SES-CD Thresholds Associated With Low Risk of Disease Progression

Predictors of histologic response to mepolizumab in pediatric eosinophilic esophagitis

Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn’s Disease: A Post Hoc Analysis of the IM-UNITI Trial

Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn’s Disease

REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study

Clinical Decision Support Tool for Infliximab in Crohn’s Disease

Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis

Suchergebnisse filtern